<DOC>
	<DOCNO>NCT02422030</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic interaction Atorvastatin Fenofibric acid .</brief_summary>
	<brief_title>CKD-337 ( 2 ) Drug-drug Interaction Study</brief_title>
	<detailed_description>This study randomize , open-label , multiple dosing , 3-way crossover design evaluate drug-drug interaction Atorvastatin ( Lipitor ) Fenofibric ( Trilipix ) acid healthy male subject . Subjects receive repeat dose Atorvastatin ( 40mg*1Tab/day ) Fenofibric acid ( 135mg*1Cap/day ) Atorvastatin ( 40mg*1Tab/day ) /Fenofibric acid ( 135mg*1Cap/day ) . Each treatment period separate washout period least 8 day .</detailed_description>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Healthy man old 19 year time screen . BMI 17.5kg / m2 le 30.5kg / m2 weight 55kg Subject without congenital chronic disease psychotic symptom finding medical examination . Suitable subject determine laboratory test hematology test , blood chemistry , urinalysis test accord characteristic drug screen test ECG test . Subject fully understand clinical trial indepth explanation give prior clinical study , decide join clinical trial sign consent form approve Chonbuk National University Hospital IRB . Subjects able comply schedule visit , laboratory test procedure . 1 . Subject history blood , kidney , endocrine , respiratory , gastrointestinal , urinary , cardiovascular , hepatic , psychiatric , neurological allergic disease clinically significant ( Except untreated asymptomatic seasonal allergy time administration ) 2 . Subject history gastrointestinal disease gastrointestinal surgery affect drug absorption . 3 . Showing value correspond follow laboratory parameter : AST AST CK &gt; 2* upper limit normal range . 4 . Alcohol &gt; 210g/week , within 6 month prior screen . 5 . Taking medication involve clinical trial within two month first dose medication character . 6 . Sitting Systolic Blood Pressure ≥ 140 mmHg , Diastolic Blood Pressure ≥ 90 mmHg time screen . 7 . History alcohol drug abuse , within 1 year 8 . Subjects treat metabolize enzyme inducer inhibitor barbital within 30days prior first dosing . 9 . Smoker ( &gt; 20cigarettes/day ) 10 . Subjects take ETC OTC medicine within 10days first IP administration . 11 . Subject do whole blood donation within two month component blood donation within 1 month within 1 month prior first dose . 12 . Subject increase risk due clinical test administration drug Severe grade / chronic medical , mental condition abnormal laboratory result may interfere analysis test result . 13 . Subject serious history hypersensitivity allergy investigational product . 14 . Active liver disease . 15 . Muscle disease . 16 . Subject genetic problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . 17 . Patients severe hepatic impairment Gallbladder Disease . 18 . Patients moderate severe renal impairment . 19 . Patients experience allergy phototoxicity treatment fibrate ketoprofen . 20 . Subjects able comply guideline describe protocol . 21 . Subjects determine investigator 's decision unsuitable clinical trial participation .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Male Volunteers</keyword>
</DOC>